Repository logo
 

Loss of FBXO7 results in a Parkinson’s-like dopaminergic degeneration via an RPL23-MDM2-TP53 pathway

Published version
Peer-reviewed

Type

Article

Change log

Authors

Stott, Simon 
Randle, Suzanne 
Al Rawi, Sara 
Rowicka, Paulina 

Abstract

The field of Parkinson’s disease research has been impeded by the absence of animal models that clearly phenocopy the features of this neurodegenerative condition. Mutations in FBXO7/PARK15 are associated with both sporadic Parkinson’s disease and a severe form of autosomal recessive early-onset Parkinsonism. Here we report that conditional deletion of Fbxo7 in the midbrain dopamine neurons results in an early reduction in striatal dopamine levels, together with a slow, progressive loss of midbrain dopamine neurons and onset of locomotor defects. Unexpectedly, a later compensatory response led to a near-full restoration of dopaminergic fibre innervation in the striatum, but nigral cell loss was irreversible. Mechanistically, there was increased expression in the dopamine neurons of FBXO7-interacting protein, RPL23, which is a sensor of ribosomal stress that inhibits MDM2, the negative regulator of p53. A corresponding activated p53 transcriptional signature biased towards pro-apoptotic genes was also observed. These data suggest the neuroprotective role of FBXO7 involves its suppression of the RPL23-MDM2-p53 axis that promotes cell death in dopaminergic midbrain neurons.

Description

Keywords

FBXO7/PARK15, Parkinson's disease, Rpl23-Mdm2-p53 axis, dopaminergic neurons, Animals, Behavior, Animal, Disease Models, Animal, Dopaminergic Neurons, F-Box Proteins, Female, Locomotion, Male, Mesencephalon, Mice, Inbred C57BL, Mice, Knockout, Motor Activity, Nerve Degeneration, Parkinson Disease, Proto-Oncogene Proteins c-mdm2, Ribosomal Proteins, Signal Transduction, Tumor Suppressor Protein p53

Journal Title

Journal of Pathology

Conference Name

Journal ISSN

1096-9896
1096-9896

Volume Title

249

Publisher

John Wiley & Sons Inc.
Sponsorship
Biotechnology and Biological Sciences Research Council (BB/J007846/1)
Royal Society (RG2010/R2)
Rosetrees Trust (A784)
Parkinson's UK (G-1701)
Medical Research Council (MC_PC_12009)
Biotechnology and Biological Sciences Research Council (BB/J007846/1), DDPDgenes, Parkinson's UK and the CurePD Trust, and Wellcome Trust-MRC funded Cambridge Stem Cell Institute and an NIHR award of a Biomedical Research Centre for Addenbrooke’s Hospital/University of Cambridge.